1

#### 1 Managing Central Venous Access during a Healthcare Crisis

2

| 3  | Tristen T. Chun, MD, MS <sup>1</sup> Dejah R. Judelson, MD <sup>2</sup> , David Rigberg, MD, <sup>1</sup> Peter F Lawrence,                             |
|----|---|
| 4  | MD, <sup>1</sup> Robert Cuff, MD, <sup>3</sup> Sherene Shalhub, MD, MPH, <sup>4</sup> Max Wohlauer, MD, <sup>5</sup> Christopher J.                     |
| 5  | Abularrage, MD, <sup>6</sup> Papapetrou Anastasios, MD, PhD, MSc, <sup>7</sup> Shipra Arya, MD, SM, <sup>8</sup> Bernadette                             |
| 6  | Aulivola, MD, MS, <sup>9</sup> Melissa Baldwin, MD, <sup>10</sup> Donald Baril, MD, <sup>1</sup> Carlos F. Bechara, MD, <sup>9</sup>                    |
| 7  | William E. Beckerman, MD, <sup>11</sup> Christian-Alexander Behrendt, MD, <sup>12</sup> Filippo Benedetto, MD, <sup>13</sup>                            |
| 8  | Lisa F. Bennett, MD, MS, <sup>14</sup> Kristofer M. Charlton-Ouw, MD, <sup>15</sup> Amit Chawla, MD, <sup>16</sup> Matthew                              |
| 9  | C. Chia, MD, <sup>17</sup> Sungsin Cho, MD, PhD, <sup>18</sup> Andrew M.T.L. Choong, MBBS, PhD, <sup>19</sup> Elizabeth L.                              |
| 10 | Chou, MD, <sup>20</sup> Anastasiadou Christiana, MD, <sup>7</sup> Raphael Coscas, MD, PhD, <sup>21</sup> Giovanni De Caridi                             |
| 11 | MD, PhD, <sup>13</sup> Sharif Ellozy, MD, <sup>22</sup> Yana Etkin, MD, <sup>23</sup> Peter Faries, MD, <sup>10</sup> Adrian T. Fung, MD, <sup>24</sup> |
| 12 | Andrew Gonzalez, MD, JD, MPH, <sup>25</sup> Claire L. Griffin, MD, <sup>26</sup> , London Guidry, MD, <sup>16</sup> Nalaka                              |
| 13 | Gunawansa, MBBS, MS, MCh, <sup>27</sup> Gary Gwertzman, MD, <sup>10</sup> Daniel K. Han, MD, <sup>10</sup> Caitlin W.                                   |
| 14 | Hicks, MD MS, <sup>6</sup> Carlos A. Hinojosa MD, MSc, <sup>28</sup> York Hsiang, MB, ChB, MHSc, <sup>24</sup> Nicole                                   |
| 15 | Ilonzo, MD, <sup>10</sup> Lalithapriya Jayakumar, MD, <sup>29</sup> Jin Hyun Joh, MD, PhD, <sup>18</sup> Adam P. Johnson, MD,                           |
| 16 | MPH, <sup>30</sup> Loay S. Kabbani, MD, MHSA, <sup>31</sup> Melissa R. Keller, MD, PhD, <sup>32</sup> Manar Khashram,                                   |
| 17 | MBChB, PhD, <sup>33</sup> Issam Koleilat, MD, <sup>34</sup> Bernard Krueger, MD, <sup>35</sup> Akshay Kumar, MD, <sup>36</sup> Cheong                   |
| 18 | Jun Lee, MD, <sup>37</sup> Alice Lee, DO, <sup>31</sup> Mark M. Levy, MD, <sup>38</sup> C. Taylor Lewis, MD, <sup>22</sup> Benjamin Lind,               |
| 19 | MD, <sup>37</sup> Gabriel Lopez-Pena, MD, <sup>28</sup> Jahan Mohebali, MD, MPH, <sup>20</sup> Robert G. Molnar, MD, MS, <sup>32</sup>                  |
| 20 | Nicholas J. Morrissey, MD, <sup>30</sup> Raghu L. Motaganahalli, MD, <sup>25</sup> Nicolas J. Mouawad, MD, MPH,   |
| 21 | MBA, <sup>32, 39</sup> Daniel H. Newton, MD, <sup>38</sup> Jun Jie Ng, MD, <sup>19</sup> Leigh Ann O'Banion, MD, <sup>40</sup> John Phair,              |
| 22 | MD, <sup>10</sup> Zoran Rancic, MD, MSc, PhD, <sup>35</sup> Ajit Rao, MD, <sup>10</sup> Hunter M. Ray, MD, <sup>15</sup> Aksim G.                       |
| 23 | Rivera MD <sup>34</sup> Limael Rodriguez MD <sup>5</sup> Clifford M Sales MD MBA <sup>41</sup> Garrett Salzman MD $^1$                                  |

23 Rivera, MD,<sup>34</sup> Limael Rodriguez, MD,<sup>5</sup> Clifford M. Sales, MD, MBA,<sup>41</sup> Garrett Salzman, MD,<sup>1</sup>

Chun, T. T., Judelson, D. R., Rigberg, D., Lawrence, P. F., Cuff, R., Shalhub, S., Wohlauer, M., Abularrage, C. J., Anastasios, P., Arya, S., Aulivola, B., Baldwin, M., Baril, D., Bechara, C. F., Beckerman, W. E., Behrendt, C.-A., Benedetto, F., Bennett, L. F., Charlton-Ouw, K. M., ... Woo, K. (2020). Managing Central Venous Access during a Healthcare Crisis. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2020.06.112

This is the author's manuscript of the work published in final edited form as:

| 1  | Mark              | Sarfati, MD, <sup>26</sup> Ajay Savlania, MCh, <sup>42</sup> Andres Schanzer, MD, <sup>2</sup> Mel J. Sharafuddin, MD,              |
|----|-------------------|---|
| 2  | MS, <sup>43</sup> | Malachi Sheahan, MD, <sup>16</sup> Sammy Siada, DO, <sup>5</sup> Jeffrey J. Siracuse, MD, MBA, <sup>44</sup> Brigitte K.            |
| 3  | Smith,            | MD, <sup>26</sup> Matthew Smith, MD, PhD, <sup>22</sup> Ina Soh, MD, MS, <sup>45</sup> Rebecca Sorber, MD, <sup>6</sup> Varuna      |
| 4  | Sunda             | ram, MD, <sup>22</sup> Scott Sundick, MD, MS, <sup>41</sup> Tadaki M. Tomita, MD, <sup>17</sup> Bradley Trinidad, MD, <sup>46</sup> |
| 5  | Shirlir           | ng Tsai, MD, <sup>47</sup> Ageliki G. Vouyouka, MD, <sup>10</sup> Gregory G. Westin, MD, MAS, <sup>25</sup> Michael S.              |
| 6  | Willia            | ms Jr., MD, <sup>48</sup> Sherry M. Wren, MD, <sup>8</sup> Jane K. Yang, MD, <sup>1</sup> Jeniann Yi, MD, MS, <sup>5</sup> Wei      |
| 7  | Zhou,             | MD, <sup>46</sup> Saqib Zia, MD, <sup>49</sup> Karen Woo MD, MS, <sup>1</sup>   |
| 8  |                   |   |
| 9  |                   |   |
| 10 | 1.                | Department of Surgery, Division of Vascular Surgery, David Geffen School of Medicine  |
| 11 |                   | at UCLA, Los Angeles, CA  |
| 12 | 2.                | Department of Surgery, Division of Vascular and Endovascular Surgery, University of   |
| 13 |                   | Massachusetts Medical School, Worcester, MA   |
| 14 | 3.                | Department of Surgery, Division of Vascular Surgery, Spectrum Health/ Michigan State  |
| 15 |                   | University, Grand Rapids, MI  |
| 16 | 4.                | Department of Surgery, Division of Vascular Surgery, University of Washington, Seattle,   |
| 17 |                   | WA  |
| 18 | 5.                | Department of Surgery, Division of Vascular Surgery, University of Colorado School of   |
| 19 |                   | Medicine, Aurora, CO  |
| 20 | 6.                | Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Johns   |
| 21 |                   | Hopkins Medical Institutions, Baltimore, MD   |
| 22 | 7.                | Department of Vascular Surgery, General Hospital of Athens KAT, Athens, Greece  |
| 23 | 8.                | Department of Surgery Stanford University School of Medicine, Palo Alto, CA, CA   |
|    |                   |   |

| 1  | 9. Department of Surgery, Division of Vascular Surgery and Endovascular Therapy, Loyola    |
|----|--|
| 2  | University Medical Center, Maywood, IL   |
| 3  | 10. Department of Surgery, Division of Vascular Surgery, Icahn School of Medicine at       |
| 4  | Mount Sinai, New York, NY  |
| 5  | 11. Department of Surgery, Division of Vascular Surgery and Endovascular Therapy,          |
| 6  | Rutgers Robert Wood Johnson, New Brunswick, NJ   |
| 7  | 12. Department of Vascular Medicine, Research Group GermanVasc, University Medical         |
| 8  | Center Hamburg-Eppendorf, Hamburg, Germany   |
| 9  | 13. Division of Vascular Surgery, University of Messina, Messina, Italy                    |
| 10 | 14. Rose Medical Center, HealthOne, Denver, CO   |
| 11 | 15. Department of Cardiothoracic and Vascular Surgery, McGovern Medical School at          |
| 12 | University of Texas Health Science Center at Houston, Houston, TX                          |
| 13 | 16. Department of Surgery, Division of Vascular Surgery, Louisiana State University Health |
| 14 | Sciences Center, New Orleans, LA   |
| 15 | 17. Department of Surgery, Division of Vascular Surgery, Northwestern University, Chicago, |
| 16 | IL   |
| 17 | 18. Department of Surgery, Division of Vascular Surgery, Kyung Hee University School of    |
| 18 | Medicine, Seoul, South Korea   |
| 19 | 19. Division of Vascular and Endovascular Surgery, National University Heart Centre,       |
| 20 | Singapore, Singapore   |
| 21 | 20. Department of Surgery, Division of Vascular Surgery, Massachusetts General Hospital,   |
| 22 | Boston, MA   |

| 1  | 21. Vascular Surgery Department, Ambroise Paré University Hospital, AP-HP, Boulogne-      |
|----|---|
| 2  | Billancourt, Paris, France  |
| 3  | 22. Department of Surgery, Division of Vascular and Endovascular Surgery, Weill Cornell   |
| 4  | Medicine, New York, NY  |
| 5  | 23. Department of Surgery, Division of Vascular and Endovascular Surgery, Zucker School   |
| 6  | of Medicine at Hofstra/Northwell, Hempstead, NY   |
| 7  | 24. Department of Surgery, Division of Vascular Surgery, University of British Columbia,  |
| 8  | Vancouver, CA   |
| 9  | 25. Department of Surgery, Division of Vascular Surgery, Indiana University School of     |
| 10 | Medicine, Indianapolis, IN  |
| 11 | 26. Department of Surgery, Vascular Division, University of Utah, Salt Lake City, UT      |
| 12 | 27. Department of Vascular and Transplant Surgery, National Institute of Nephrology,      |
| 13 | Dialysis and Transplantation, Colombo, Sri Lanka  |
| 14 | 28. Department of Surgery, Division of Vascular and Endovascular Surgery, Universidad     |
| 15 | Nacional Autónoma de México, Instituto Nacional de Ciencias Médicas y Nutrición           |
| 16 | Salvador Zubirán, CDMX, MX  |
| 17 | 29. Department of Surgery, Vascular and Endovascular Division, University of Texas Health |
| 18 | Science Center at San Antonio, San Antonio, TX  |
| 19 | 30. Department of Vascular Surgery, Columbia University Valegos College of Physicians     |
| 20 | and Surgeons, New York, NY  |
| 21 | 31. Department of Surgery, Vascular Division, Wayne State University, Detroit, MI         |
| 22 | 32. Department of Surgery, Michigan State University, East Lansing, MI                    |
| 23 | 33. Department of Surgery, University of Auckland, Auckland, New Zealand                  |

| 1  | 34. Department of Cardiothoracic and Vascular Surgery, Montefiore Medical Center/Albert     |
|----|---|
| 2  | Einstein College of Medicine, Bronx, NY   |
| 3  | 35. Institute of Anesthesiology, Intensive Care Unit for Cardiovascular Surgery, University |
| 4  | Hospital Zurich, Faculty of Medicine, University of Zurich, Zurich, Switzerland             |
| 5  | 36. Department of Cardiovascular and Thoracic Surgery, Medanta Hospital, Gurgaon, India     |
| 6  | 37. Department of Surgery, Division of Vascular Surgery, NorthShore University Health       |
| 7  | System, Evanston, IL  |
| 8  | 38. Department of Surgery, Vascular Division, Virginia Commonwealth University,             |
| 9  | Richmond, VA  |
| 10 | 39. Vascular and Endovascular Surgery, McLaren Health System, Bay City, MI                  |
| 11 | 40. Department of Surgery, Vascular Division, University of California San Francisco at     |
| 12 | Fresno, Fresno, CA  |
| 13 | 41. The Cardiovascular Care Group, New Jersey   |
| 14 | 42. Postgraduate Institute of Medical Education and Research, Chandigarh, India             |
| 15 | 43. Department of Vascular Surgery, University of Iowa Healthcare, Iowa City, IA            |
| 16 | 44. Department of Surgery, Boston University School of Medicine, Boston, MA                 |
| 17 | 45. Division of Vascular and Endovascular Surgery, Mayo Clinic, Phoenix, AZ                 |
| 18 | 46. Department of Surgery, Vascular Division, University of Arizona, Tucson, AZ             |
| 19 | 47. Department of Surgery, Vascular Division, VA North Texas Health Care Systems, Dallas    |
| 20 | TX  |
| 21 | 48. Department of Surgery, Vascular and Endovascular Division, St. Louis University School  |
| 22 | of Medicine, St. Louis, MO  |

| 1  | 49. Department of Surgery, Vascular Division, Rutgers New Jersey Medical School, Newark, |
|----|--|
| 2  | NJ   |
| 3  |  |
| 4  |  |
| 5  |  |
| 6  | Corresponding author:  |
| 7  | Karen Woo, MD  |
| 8  | University of California, Los Angeles  |
| 9  | Department of Surgery  |
| 10 | Division of Vascular Surgery   |
| 11 | 200 UCLA Medical Plaza Ste 526   |
| 12 | Los Angeles, CA 90095  |
| 13 | Office (310) 206-6294  |
| 14 | Email kwoo@mednet.ucla.edu   |
| 15 | ARTICLE HIGHLIGHTS   |
| 16 |  |
| 17 | Type of Research: Multi-center cross sectional cohort                                    |
| 18 | study of experiences with central venous access line                                     |
| 19 | teams during the COVID-19 pandemic.  |
| 20 |  |
| 21 | Key Findings: Participants from 60 hospitals in 13                                       |
| 22 | countries contributed data. 75% of line teams included a                                 |
| 23 | vascular surgery attending physician. 2,657 central                                      |

| 1  | venous lines were placed at 20 of the participating sites                                      |
|----|--|
| 2  | with 11 (0.41%) iatrogenic access complications  |
| 3  | associated with procedures performed by the line team.   |
| 4  |  |
| 5  | Take home Message: Implementation of a dedicated   |
| 6  | central venous access line team during health care   |
| 7  | emergencies, with staffing by physicians with central  |
| 8  | venous access expertise, a dedicated line cart, specific                                       |
| 9  | anatomic sites for different venous access needs, and a  |
| 10 | method to track complications, can improve outcomes  |
| 11 | and reduce iatrogenic complications.   |
| 12 |  |
| 13 |  |
| 14 |  |
| 15 |  |
| 16 | Table of Contents Summary  |
| 17 |  |
| 18 | Implementation of dedicated central venous access line teams during health care emergencies,   |
| 19 | with staffing by physicians with central venous access expertise, a dedicated line cart,       |
| 20 | recommended sites for access, and a method to track complications, can improve access delivery |
| 21 | and may reduce the risk of iatrogenic complications and mortality.                             |

#### 1 Abstract

*Introduction:* During the COVID-19 pandemic, central venous access line teams were
implemented at many hospitals throughout the world to provide access for critically ill patients.
The objective of this study was to describe the structure, practice patterns and outcomes of these
vascular access teams during the COVID-19 pandemic.

*Methods:* We conducted a cross sectional, self-reported study of central venous access line teams in hospitals afflicted with the COVID-19 pandemic. In order to participate in the study, hospitals were required to meet one of the following criteria: a) development of a formal plan for a central venous access line team during the pandemic, b) implementation of a central venous access line team during the pandemic, c) placement of central venous access by a designated practice group during the pandemic as part of routine clinical practice, or d) management of an iatrogenic complication related to central venous access in a patient with COVID-19.

Results: Participants from 60 hospitals in 13 countries contributed data to the study. Central 13 14 venous line teams were most commonly composed of vascular surgery and general surgery 15 attending physicians and trainees. Twenty sites had 2,657 lines placed by their central venous access line team or designated practice group. During that time, there were 11 (0.4%) iatrogenic 16 complications associated with central venous access procedures performed by the line team or 17 group at those 20 sites. Triple lumen catheters, Cordis® catheters and non-tunneled hemodialysis 18 19 catheters were the most common types of central venous lines placed by the teams. Eight (14%) 20 sites reported experience placing central venous lines in prone, ventilated patients with COVID-19. A dedicated line cart was used by 35 (59%) of hospitals. Less than 50% (24, 41%) of the 21 participating sites reported managing thrombosed central lines in COVID-patients. Twenty-three 22

of the sites managed 48 iatrogenic complications in patients with COVID-19 (including 1 2 complications caused by providers outside of the line team or designated practice group). 3 Conclusions: Implementation of a dedicated central venous access line team during a pandemic 4 or other healthcare crisis is a way by which physicians trained in central venous access can contribute their expertise to a stressed healthcare system. A line team composed of physicians 5 with vascular skill sets provides relief to resource-constrained ICU, ward, and emergency 6 7 medicine teams with a low rate of iatrogenic complications relative to historical reports. We recommend that a plan for central venous access line team implementation be in place for future 8 healthcare crises. 9

10

11

12

## **Introduction:**

| 2  | The novel coronavirus, SARS-CoV-2, has caused 7,293,307 cases of Coronavirus                                       |
|----|--|
| 3  | Disease 2019 (COVID-19) worldwide (as of June 10, 2020) and 413,126 deaths. Of those cases,                        |
| 4  | 1,990,112 have been in the United States with 112,441 associated deaths between February 6,                        |
| 5  | 2020 and June 10, 2020 <sup>1</sup> . Approximately 5-10% of patients with COVID-19 require admission to           |
| 6  | the intensive care unit and mechanical ventilation <sup>2-3</sup> . In these critically ill patients, the rates of |
| 7  | septic shock and acute kidney injury are 20% and 15%, respectively <sup>4-5</sup> . As a result, these patients    |
| 8  | often require central venous access for the infusion of vasoactive agents and/or hemodialysis.                     |
| 9  | In the COVID-19 crisis, overburdened health care systems throughout the world have had                             |
| 5  | In the COVID 17 clisis, overbuildened health care systems throughout the world have had                            |
| 10 | to address the need to provide central venous access for the unprecedented dramatic influx of                      |
| 11 | critically ill patients, particularly during the surge period of the pandemic. As a result, the                    |
| 12 | procedure of placing central venous access, which is normally a routine occurrence in critical                     |
| 13 | care units, has created unique challenges during the COVID-19 pandemic given the limited                           |
| 14 | providers available to manage the extraordinary increase in critically ill patients. The limited                   |
| 15 | resources may lead to central venous access procedures being performed by less experienced                         |
| 16 | and/or overworked physicians, which results in an increased rate of serious complications <sup>6</sup> .           |
| 17 | Furthermore, central venous access procedures can result in physicians being occupied for a                        |
| 18 | prolonged period by a single patient while the issues of other acutely ill patients are not being                  |
| 19 | addressed. In the case of a COVID-19 positive patient, the central venous access procedure                         |
| 20 | includes not only the time required to perform the procedure, but also the additional time                         |
| 21 | required to don and doff the added personal protective equipment required.   |

1 During the COVID-19 pandemic, central venous access line teams have been developed 2 at many hospitals throughout the world to handle the access needs of all patients in the hospital, freeing physicians with less experience in central venous access and those who are overburdened 3 by acute and critical demands to focus on management of other patients requiring their attention<sup>7-</sup> 4 <sup>8</sup>. The teams often consist of vascular surgeons, general surgeons, interventional radiologists, 5 6 anesthesiologists, intensivists, and interventional cardiologists who have been trained and have extensive experience in central venous access, as well as experience identifying and managing 7 the complications associated with central venous access procedures<sup>9-10</sup>. For example, to meet the 8 9 increased demand for critical care providers at the University of Massachusetts, vascular 10 surgeons formed a "Surgical Workforce Access Team (SWAT)" in order to best leverage the skillsets of vascular surgery division members and provide the best service to the hospital and to 11 their colleagues<sup>7</sup>. At Mount Sinai Hospital in New York, physicians recognized a dramatic 12 13 increase in the rate of central line complications and the resulting urgent vascular interventions. In response, the vascular surgeons created a line team<sup>8</sup>. 14 15 While central line teams and protocols for line placement and management have been

described in the past, those efforts have been focused on reducing central line-associated
bloodstream infections rather than addressing a pressing need during a healthcare disaster<sup>11-13</sup>.
Within the context of early isolated single-institution reports, we sought to provide a multiinstitutional experience of line teams during the pandemic. The objective of this study was to
describe the structure, practice patterns, and outcomes of these line teams on central venous
access procedures and their related complications.

#### 22 Methods:

| 1  | We conducted a cross-sectional, self-reported study of structured central venous access                  |
|----|--|
| 2  | line teams and the physician groups providing central venous access in hospitals afflicted by the        |
| 3  | COVID-19 pandemic. In order to participate in the study, hospitals were required to meet one of          |
| 4  | the following criteria: a) development of a formal plan for a central venous access line team            |
| 5  | during the pandemic, b) implementation of a central venous access line team during the                   |
| 6  | pandemic, c) placement of central venous access by a designated practice group during the                |
| 7  | pandemic as part of routine clinical practice, or d) management of an iatrogenic complication            |
| 8  | related to central venous access in a patient with COVID-19  |
| 9  | This study was a collaborative effort between the Vascular Low Frequency Disease                         |
| 10 | Consortium (VLFDC) and the Vascular Surgery COVID-19 Collaborative (VASCC). The                          |
| 11 | VLFDC is a multi-institutional collaboration, initiated 20 years ago, and designed to investigate        |
| 12 | uncommon vascular diseases <sup>14</sup> . The VASCC was established on March 2, 2020 to study the       |
| 13 | impact of the ongoing COVID-19 pandemic on vascular surgical care <sup>15</sup> , using an international |
| 14 | registry.  |
| 15 | The Institutional Review Board of the University of California Los Angeles (UCLA)                        |
|    |  |
| 16 | deemed this study protocol exempt as a quality improvement project.                                      |
| 17 | Database development   |
| 18 | The primary investigators (KW, TC, DJ, DR) initially developed the registry data                         |
| 10 |  |
| 19 | elements by determining factors important to the structure and function of central venous access         |
| 20 | line teams' experience of line placement during the pandemic, as well as iatrogenic                      |
| 21 | complications associated with line placement. The draft registry was reviewed by a group of              |
| 22 | physician investigators with central venous line placement expertise and revised in an iterative         |
|    |  |

fashion until no further modifications were recommended by the group. This established the final
 standardized dataset for collection that constitutes the basis of this study.

3 *Data collection* 

The study was disseminated through the VLFDC and VASCC electronic mailing lists and social media. Study data were collected and managed using REDCap (Research Electronic Data Capture), a web-based data collection mechanism designed for research<sup>16</sup>. Data entry into the registry opened on April 22, 2020 and closed on May 4, 2020. Study participants were required to record responses to all items in the database. Participants were contacted via electronic mail by the UCLA vascular research center for clarification of any discrepancies in the submitted data and missing data.

11 Participants were required to enter their hospital characteristics, utilization of central venous access line teams during the pandemic, types of patients and locations in which the line 12 team services were offered, team composition, team availability, criteria for activation and 13 14 termination of their services, and anatomic sites used for access. Each institution was asked to provide details regarding any iatrogenic complications associated with central venous line 15 16 placement, and if available, the total number of central venous access procedures performed 17 during the time that the line team or designated practice group placing central lines was in place. Each institution was also given the opportunity to provide insight regarding successful 18 management of central venous access during the pandemic. 19

#### 20 <u>Results</u>

#### 21 Demographics

Participants from 60 hospitals in 13 countries contributed data to the study 1 2 (Appendix A). Fifty-eight of the hospitals had plans in place for a central venous access line team, had implemented the line team, or had a designated practice group placing central venous 3 lines for the hospital outside of a formal line team structure. Two of the participating hospitals 4 had not developed or implemented a line team or designated a group to place lines, but had 5 managed an iatrogenic complication related to central venous access in a patient with COVID-6 7 19. Most of the hospitals that participated were urban, academic, university-affiliated hospitals 8 with more than 400 beds (Table 1). Thirty-one of the hospitals had developed and implemented a 9 central venous access line team specifically for the pandemic, while five hospitals had a plan for 10 a line team but had not yet implemented it. Twenty-five of the participating hospitals had a physician group placing central venous lines as part of their routine clinical practice, without 11 being designated as a "line team." Eight of the hospitals that implemented a line team had a 12 13 central venous access line team in existence prior to the pandemic, with four making no changes once the pandemic started. Two changed the PPE protocols for their line teams with the onset of 14 15 the pandemic. One made services available on the weekends and ensured that attending physicians were physically present in the hospital at all times. One had a pre-existing medical 16 proceduralist team which remained in place with the addition of a surgical team to supplement or 17 take over their responsibilities when the medical specialists get called to take care of patients. 18

Central venous access line teams were most commonly composed of vascular and
general surgery attending physicians and trainees, with some hospitals including attending
physicians and trainees of other specialties such as interventional radiology and anesthesiology
(Figure 1). Nearly all of the line teams were developed served or intended to serve patients who
had tested positive for the SARS-CoV-2 virus (COVID-19+) in the intensive care unit setting

(ICU) (42, 96%) as well as patients under investigation for SARS-CoV-2 infection (COVID19PUI) in the ICU (40, 90%). Fewer line teams included patients who had tested negative for the
SARS-CoV-2 virus (COVID-19-) in the ICU (28, 66%). Most line teams also provided service
for COVID-19+ and COVID-19PUI patients on the floor setting (28, 64%). Some line teams
provided services for COVID-19+ (25, 57%) and COVID-19PUI (22, 50%) patients in the
emergency department.

7 The plan to utilize the services of a central venous access line team during the pandemic was most commonly initiated by the vascular surgery division/department (15, 34%) or critical 8 care team (11, 25%). The burden of COVID-19+ patients exceeding a critical threshold at the 9 10 institution, where providers with training were present but overwhelmed, was cited as one of the reasons for implementing the line team by 22 (50%) of hospitals. The importance of minimizing 11 12 line placement complications was cited as one of the reasons for implementation by 23 (52%) of 13 hospitals. The majority of line teams made their services available daily at all hours (28, 64%), while at some hospitals (5, 12%), the timing of line team service availability varied by the phase 14 of the pandemic and the stress on the resources in their hospital. These hospitals required 15 exceeding a critical volume threshold for the central venous access line team to become 16 17 activated. The criteria for terminating the line team services included a combination of: 1) 18 reduction of hospitalized COVID patients to below a critical threshold (64%), 2) increased 19 availability of other providers with line placement skills (25%), and 3) line team members 20 returning to regular duties (41%).

21 Central venous access line team characteristics

In the 58 hospitals placing lines, six sites (10%), had no trainees involved in
 central venous line placement procedures. At eleven hospitals (19%), the attending physician
 was in the room during every line placement procedure. Of the 41 remaining hospitals, 30 had
 trainees that were at least at post-graduate year three level performing the central venous access
 procedures, with attending physicians immediately available.

Triple lumen catheters (TLCs), Cordis® catheters, non-tunneled hemodialysis catheters
(NTHDCs) and tunneled hemodialysis catheters (THDCs) were the most common types of
central venous lines placed (Figure 2). Six of the hospitals also performed peripherally inserted
central catheters (PICC); however, they reported that this practice was in place prior to the
pandemic and remained unchanged.

11 Among the 44 hospitals with line teams in place or planned, additional line team services 12 provided, beyond central venous line placement during the COVID-19 pandemic, included: arterial line placement (82.8%), orogastric/nasogastric tube placement (18%), tube thoracostomy 13 (16%), Foley catheter placement (10%), intubation (7%), tracheostomy (5%), gastric tube 14 placement (2%), and rectal tube placement (2%). For the 31 hospitals with line teams in place, 15 the reported numbers of central venous line placements performed over the seven days preceding 16 participation in this study varied from <10 to >40, with the most common category being >4017 (Table 1). 18

19 Anatomic considerations

The internal jugular veins were the preferred sites for TLC and hemodialysis catheter
(HDC) placement prior to the COVID-19 pandemic (Table 2); these continued to be the
preferred sites during the pandemic for COVID-19+, COVID-19PUI and COVID-19- patients.

However, during the pandemic, the participating sites used the internal jugular and subclavian
veins less frequently than prior to the pandemic, while the great saphenous (GSV) and popliteal
veins (PV) were used more frequently. For supine COVID-19+ patients, the first choice for TLC
placement was the right internal jugular vein in 31 (52.5%) hospitals and the left internal jugular
vein in 22 (37.3%). The first-choice location for HDC placement was the right internal jugular
vein in 46 (82.1%) of the hospitals. Similar patterns were found for COVID-19PUI (Table 2).

7 Most participating sites considered similar anatomic locations for COVID-19+ and COVID-19- patients; however, 18 (30.5%) sites reported that their preferences for venous access 8 in COVID-19+ patients were different from COVID-19- patients, with the most common reason 9 10 being the ease of accessibility and the likelihood of kinking the catheters if the patient required prone positioning. Other considerations included the risk of pneumothorax and the proximity to 11 12 the patient's airway, potentially increasing the risk of infection to the providers performing the 13 procedure. In addition, 16 (27%) sites considered renal failure or impending renal failure requiring dialysis as a factor in choosing anatomic location for TLCs or HDCs. Most reported 14 preserving the right internal jugular vein for HDCs and avoiding the femoral veins for HDCs for 15 potential prone positioning required for COVID-19 treatment. 16

Eight (14%) sites reported experience with placing central venous lines in prone, ventilated COVID-19+ patients, with no associated complications. Six of the sites always delayed line placement until the patient returned to the supine position, or they requested that the patient be returned to the supine position for the procedure. One site placed the lines with the patient remaining in the prone position. Two sites placed the line with the patient remaining in the prone position if they could safely access the vein laterally. In this population of patients who required prone positioning, TLCs continued to be placed in either the right or the left internal jugular veins, the femoral vein, or the great saphenous vein. HDCs were placed exclusively in
the right internal jugular vein. Three lines were placed while the patient remained in the prone
position: 1) a TLC placed in the popliteal vein, 2) a NTHDC placed in the right internal jugular
vein, and 3) a TLC placed in the right internal jugular vein. Standard line placement techniques
were used with ultrasound guidance and percutaneous Seldinger technique.

All 58 sites placing central venous lines during the COVID-19 pandemic used
ultrasound guidance during line placement and nearly all participants (52, 90%) reported
obtaining a chest X-ray (CXR) to confirm line placement for internal jugular or subclavian lines
in COVID-19+ patients. Those who did not obtain a CXR acknowledged that this deviated from
their normal practice. Their rationale for not utilizing a CXR was to limit exposure of hospital
staff and radiology technologists, while conserving personal protective equipment (PPE).

#### 12 Supplies and PPE utilization

A dedicated line cart was used at 35 (59%) hospitals. The most common items stored in these line carts were: kits for TLCs, HDCs, Cordis® catheters (100%), sterile gloves (97%), sterile gowns (97%), sterile preparation sticks (94%), sterile gauze (94%), ultrasound probe covers (94%), selection of syringes (91%), sterile saline flushes (91%), sutures (91%), masks (91%), and bouffant hats (85%) (Appendix B).

PPE utilization patterns by line teams in COVID-19+ patients and COVID-19PUI
were similar (Table 3). A small but significant number of line teams continued to use N95 masks
with or without surgical masks, even in COVID-19- patients (Table 3). When asked if hospitals
experienced an increased incidence of needle sticks to providers associated with central line

- placement during the COVID-19 pandemic, 28 (47%) responded "no" and 31 (52%) "did not
   know".
- 3 Prevention and management of thrombosed central lines

| 4 | Less than 50% (24, 41%) of the participating sites in this study reported                    |
|---|--|
| 5 | managing thrombosed central lines in COVID-19+ patients: 19 (33%) sites reported managing at |
| 6 | least one thrombosed TLC, 21 (36%) HDC, and 2 (3%) Cordis® catheters. Over half of the sites |
| 7 | (32, 54%) believed that central lines were more likely to thrombose in COVID-19+ patients,   |
| 8 | compared to COVID-19- patients, due to hypercoagulability. Most also believed that HDCs were |
| 9 | more likely to thrombose in COVID-19+ patients than any other type of central venous lines.  |

Only 13 (22%) participating sites recommended varying types of routine 10 11 anticoagulation in COVID-19+ patients to maintain central line patency, including: prophylactic 12 dosing of unfractionated heparin (4 sites), therapeutic dosing of unfractionated heparin (1 site), prophylactic dosing of low molecular weight heparin (5 sites), and therapeutic dosing of low 13 14 molecular heparin (2 sites). The two remaining hospitals anticoagulated all COVID-19+ patients, regardless of whether the patient had a central venous access line in place. The majority 15 of the participants who recommended anticoagulation were concerned about a high rate of 16 17 thrombosis in COVID-19+ patients and recommended anticoagulation to minimize resource utilization. 18

Only 7 (12%) participating sites were routinely changing central lines. Of those 7 sites, 5
reported that routine changing of lines was part of their regular practice, regardless of the
pandemic. One site changed the line every three days, one every four days, four every seven days
and one every eight days.

#### 1 *Complications and deaths*

Twenty participating sites reported 2,657 lines placed by their designated group or line team 2 in COVID-19+, COVIDPUI and/or COVID-19- patients; there were 11 (0.4%) iatrogenic 3 complications associated with central venous access line placement procedures performed by the 4 designated group or line team at those sites. These consisted of two inadvertent placements of a 5 6 catheter into an artery, seven instances of hematoma or active bleeding at catheter sites, one 7 instance of pneumothorax and one air embolism. The air embolism was in a COVID-19+ patient who was not intubated and the patient expired shortly thereafter. This was the only death directly 8 9 related to an iatrogenic venous access complication. A total of 48 iatrogenic complications of central venous line placement in the COVID-10 11 19+ population were managed by 23 (38%) participating sites, including complications 12 associated with procedures performed by providers outside of their line team or designated group (Table 4). The most common type of complication was inadvertent placement of a catheter 13 into an artery. In 20 of the complications, the participating site believed something could have 14 been done differently during the initial access attempt to prevent the complication. In almost all 15 of these cases, the participating site believed that a combination of a more experienced operator, 16

meticulous use of ultrasound, and maintaining wire control at all times could have prevented thecomplication.

With respect to the COVID-19+ population, in one case of inadvertent puncture of the
artery, the wire was left in the femoral artery and the patient was anticoagulated, since the patient
was deemed too unstable for intervention. In three of the cases of inadvertent placement of a
catheter into an artery, the patient was deemed too unstable from COVID-19 to undergo an

intervention. In all but three of the complications in the COVID-19+ population, the participating
sites indicated that they would have managed the iatrogenic complication in a COVID-19patient in a similar manner to what was done in the COVID-19+ patient. For three
complications, the sites stated they may have considered more aggressive surgical or
interventional management if the patient had not been COVID-19+.

### 6 **Discussion:**

7 We describe the formation, implementation and results of dedicated central venous access line teams led by physicians with central venous access expertise during the COVID-19 8 pandemic. These dedicated line teams served as an invaluable resource in stressed health care 9 systems. This is aptly demonstrated by the 2,657 lines placed by 20 of the line teams. Each of 10 these lines represents an instance where the line team enabled the ICU team to focus on the care 11 12 of an unprecedented high volume of critically ill patients, rather than spend time preparing for the procedure, donning and doffing PPE and performing the procedure. These line teams 13 represent "bringing together elements to ensure an effective response", which is a key point that 14 is repeatedly emphasized in disaster management<sup>17</sup>. 15

The rapid spread of the pandemic exposed a lack of disaster preparedness in hospitals worldwide<sup>18</sup>. Most healthcare disasters occur without notice<sup>19</sup>. In order to optimize outcomes during a disaster, plans for managing a disaster need to be in place prior<sup>17,19</sup>. The lessons learned from this initial line service experience can be readily applied to future healthcare crises and future surges of the COVID-19 pandemic. In fact, at the time of this writing (June 10, 2020), stay-at-home orders are being lifted across the US. Since the stay-at-home order was lifted in Arizona on May 16, cases have increased by 108% in that state with an associated increase in
 hospitalizations and strain on the healthcare system<sup>20</sup>.

Vascular surgeons are uniquely trained to lead dedicated central venous access line teams, since a vascular practice usually encompasses routine percutaneous arterial and venous access, invariably using ultrasound guidance. The technical skills necessary to perform a high volume of these procedures, with a low complication rate, are critical for these teams to be of value. Based on the experiences of the participants in this study, we have identified a set of best practices for central venous line placement during times when hospital systems are stressed by disasters such as the COVID-19 pandemic.

#### 10 Standard Practices

11 Line Team Implementation: Each institution should determine an appropriate schedule for line team activation, based on available resources and individual institutional needs. Ideally, the 12 team should be available throughout the day, and any limitations should be communicated to the 13 14 intensive care units and emergency rooms. The ramp-up and ramp-down of the line team should be individualized to the needs of the institution and the central venous access service line. A 15 16 number of participants in this study highlighted the importance of understanding variations in 17 individual institutional resource allocation, with this being a key to providing service at the optimal time and place. 18

19 Line Cart: An adequately stocked line cart increases the efficiency of line placement 20 procedures. This cart should have all the supplies and PPE necessary to safely perform central 21 venous line placements and remain outside the room to reduce cross contamination. Having an 22 appropriately stocked cart, as pointed out by a number of participants, reduces donning and doffing of PPE, minimizes potential provider exposure, and allows for a more streamlined and
 efficient placement of venous access. Appendix C demonstrates equipment we recommend on a
 line cart, including PPE.

*PPE*: It is paramount that proceduralists be provided with appropriate PPE. We found that the majority of our respondents were following best practices for PPE utilization – wearing an N95 mask, covered by a surgical mask, protective eye wear, bouffant/surgical cap, and a gown and gloves for COVID-19+ patients. A number of sites recommended that there should be no more than two providers in the room, with a "runner" outside the room, who can retrieve additional supplies as needed, in order to preserve PPE and minimize exposure.

Location of Central Lines: The preferred location of central venous access lines was 10 11 relatively consistent across respondents. Given the high incidence of acute renal failure and need 12 for acute hemodialysis in the COVID-19+ population, most centers preferably placed central lines in the left internal jugular vein, reserving the right internal jugular vein for non-tunneled 13 hemodialysis lines. Given the high rate of COVID-19+ ICU patients requiring prone positioning, 14 femoral lines were avoided; several centers reported placing popliteal vein lines in these patients. 15 Subclavian lines were also discouraged, given the known increased incidence of pneumothorax 16 over internal jugular lines. Several centers used 55cm hemodialysis lines intended for tunneled 17 placement, in a non-tunneled fashion when femoral dialysis access was needed. The cuff 18 remained outside the patient, with the intent that the extra catheter length and stiffer catheter 19 material would help to reduce kinking and displacement when the patient required prone 20 positioning. 21

Ultrasound guidance: All centers utilized ultrasound guidance when performing central 1 2 venous access. Notably, participating sites believed that over half of the iatrogenic complications they managed could have been prevented with meticulous use of ultrasound guidance. 3 Ultrasound guidance has become the standard of care in placement of central lines and should 4 continue to be used in disaster situations such as the COVID-19 pandemic, despite the additional 5 time required to thoroughly clean the machine between uses<sup>21</sup>. Participants recommended 6 confirming wire position in the long axis ultrasound view and using a sterile cover over the entire 7 8 ultrasound probe and machine during the procedure to reduce the risk of cross-contamination. Wireless ultrasound transducers may be particularly useful in this clinical scenario $^{(10)}$ . 9

10 Post Placement Confirmation: In critically ill patients, reducing complications is
11 paramount, and early identification of complications is a key to patient survival. Thus, obtaining
12 a post-procedure chest X-ray to confirm the tip location and that no pneumothorax has occurred
13 continues to be an important step used by the majority of hospitals, even in a limited resource
14 situation. Careful examination of the images by the treating physician, to rule out pneumothorax,
15 is of particular importance in intubated patients, especially with higher pressure ventilator
16 settings.

*Needlestick Prevention:* We were reassured to see that there was a low incidence of
needlestick injuries. In stressful situations, it is important to continue to practice safely,
particularly with sharps and sharps disposal. Stressful and unfamiliar working conditions, lack of
adequate protective medical/technical equipment and poor work routines are known to contribute
to needlestick injuries<sup>22</sup>. Using an experienced, well-prepared team allows for the repetition and
expertise needed to reduce needle stick injuries. During this particular pandemic, patients that are
COVID-19+ or COVID-19PUI must both be handled with the same care, caution, and PPE.

| 1  | Management of Hypercoagulability and Line Thrombosis: Hypercoagulability in the                            |
|----|--|
| 2  | COVID-19+ population is well established <sup>23-25</sup> . We found variability among hospitals in        |
| 3  | reporting their experience with thrombosed central lines; consequently, prevention strategies also         |
| 4  | differed. The majority of thrombosed lines were NTHDC, and the thrombosis presumably                       |
| 5  | occurred during continuous veno-venous hemofiltration, a known complication of a low flow                  |
| 6  | hemodialysis session <sup>26</sup> . However, we were surprised to find the large number of TLCs that also |
| 7  | thrombosed. Some participants recommended running continuous infusions of low-dose                         |
| 8  | heparinized saline through any lines that are not being used for other infusions.                          |
| 9  | <i>Complications</i> : Complications secondary to central venous line placement are always                 |
|    |  |
| 10 | expected; however, the overall complication rate of 0.4% when central venous lines are placed              |
| 11 | by dedicated line teams is significantly lower than the rate of up to 15% that has been previously         |
| 12 | published <sup>27-28</sup> . The incidence of arterial cannulation during central venous access has been   |
| 13 | reported to be in the range of 4.2%-9.3% of all line placements <sup>29</sup> . In a study of 539 central  |
| 14 | venous catheter placements under ultrasound and fluoroscopy guidance, 486 of the lines were                |
| 15 | primarily placed by a surgical trainee <sup>30</sup> . The associated complication rate was 8.4%, 93% of   |
| 16 | which were arterial punctures. This suggests a dedicated line team may not only increase                   |
| 17 | efficiency of provider utilization in a pandemic but may also reduce complications in a fragile at-        |
| 18 | risk population.   |

19 *Limitations* 

As with all studies using retrospective, self-reported data, there is a possibility of reporting error or inaccuracy. To minimize this risk we standardized the data points with specific definitions and carefully reviewed the submitted data to identify any discrepancies. All

discrepancies were clarified individually with the participating investigator. Our study would be 1 2 strengthened by a matched contemporaneous comparison group of hospitals that did not implement a central venous access line team or designate a group to place lines. Another 3 valuable comparison would be the rate of complications at participating hospitals before the 4 pandemic. However, these types of studies require a complex study design with recruitment of 5 matched hospitals and abstraction of data that was not readily available during the pandemic. 6 7 This was not feasible at the time of the study, but could be performed in the future to quantify the impact of line teams on the incidence of iatrogenic central venous access complications. Lacking 8 this, we relied on historical data in the literature for iatrogenic complication rates of central 9 10 venous line procedures and anatomical preferences for central venous line placement.

This data was collected at the height of the pandemic for many participating institutions. 11 12 As such, we sought to describe practice patterns that could possibly be useful to other institutions 13 in preparing for future waves of the pandemic or other health care crises, using data that was easily accessible to participating institutions during the potentially chaotic time. This study 14 serves as a hypothesis-generating study that brings up several granular issues relevant to the 15 16 effectiveness of line teams, requiring more laborious data extraction that should be investigated in the future. A study examining the cost effectiveness of maintaining a line cart and dedicating 17 18 personnel to line teams, balanced against the potential decrease in procedural complications and 19 increased efficiency, would provide insight into the financial burden of implementing this 20 intervention. Comparing the degree of change in volume of central line placements before the pandemic to during the pandemic, when the line teams were in place, would quantify the 21 magnitude of the line placement challenge. 22

1 The unit of analysis in this study was the hospital. Patient-specific data were collected 2 only in the case of complications and line placement in prone patients. Future studies utilizing 3 patient-specific data addressing issues such as whether the rates of line sepsis were influenced by 4 the pandemic would provide further insight into the impact of the pandemic on management of 5 central venous access.

As physicians learn more about managing patients with COVID-19, practice patterns may
change with regard to line team structure and function, preferred anatomic locations and other
technical issues. A follow-up study in the future regarding "lessons learned" from central venous
access during the pandemic and the associated changes in practice patterns in response would be
valuable.

#### 11 <u>Conclusion:</u>

The implementation of a dedicated central venous access line team is a way in which 12 physicians trained in percutaneous central venous access can make a contribution to a stressed 13 14 healthcare system during a pandemic or other healthcare crisis. A line team composed of physicians with vascular skill sets provides relief to resource-constrained ICU, ward, and 15 16 emergency medicine teams with a low rate of iatrogenic complications relative to historical 17 reports. We recommend that a plan for central venous access line team implementation be in place for future healthcare emergencies; including staffing, a dedicated line cart, 18 recommendations on the optimal anatomic site and technique, as well as a method to track 19 complications. 20

21

## 1 Acknowledgements:

- 2 We are deeply grateful Gabriela Flores for her unfailing dedication as project coordinator.
- 3 We thank Morad Sallam, M.D. for assistance in testing and refining the data collection

4 instrument.

- 5 The project described was supported by the National Center for Advancing Translational
- 6 Sciences (NCATS), National Institutes of Health (NIH), through grant UL1TR001881 and the
- 7 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of
- 8 Health (NIH) (NIDDK1K08DK107934).

9

# 1 <u>References:</u>

| 2  | 1. | COVID-19 Dashboard by the Center for Systems Science and Engineering at Johns            |
|----|----|--|
| 3  |    | Hopkins University. Available at:  |
| 4  |    | https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299       |
| 5  |    | <u>423467b48e9ecf6</u> , Accessed 10 <sup>th</sup> June 2020.                            |
| 6  | 2. | Pericàs JM, Hernandez-Meneses M, Sheahan TP, Quintana E, Ambrosioni J, Sandoval E,       |
| 7  |    | et al. COVID-19: from epidemiology to treatment. Eur Heart J. 2020;41(22):2092 2112.     |
| 8  | 3. | Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus         |
| 9  |    | Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases           |
| 10 |    | From the Chinese Center for Disease Control and Prevention [published online ahead of    |
| 11 |    | print, 2020 Feb 24]. JAMA. 2020;10.1001/jama.2020.2648.                                  |
| 12 | 4. | Ng JJ, Luo Y, Phua K, Choong AMTL. Acute kidney injury in hospitalized patients with     |
| 13 |    | coronavirus disease 2019 (COVID-19): A meta-analysis [published online ahead of print,   |
| 14 |    | 2020 May 8]. J Infect. 2020;S0163-4453(20)30280-2.                                       |
| 15 | 5. | Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for     |
| 16 |    | mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort      |
| 17 |    | study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published   |
| 18 |    | correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet.                      |
| 19 |    | 2020;395(10229):1054 🗆 1062.   |
| 20 | 6. | Vannucci A, Jeffcoat A, Ifune C, Salinas C, Duncan JR, Wall M. Special article: retained |
| 21 |    | guidewires after intraoperative placement of central venous catheters. Anesth Analg.     |
| 22 |    | 2013;117(1):102 \[] 108.   |
|    |    |  |

| 1  | 7.  | Sheth PD, Simons JP, Robichaud DI, Ciaranello AL, Schanzer A. Development of a             |
|----|-----|--|
| 2  |     | surgical workforce access team in the battle against COVID-19 [published online ahead      |
| 3  |     | of print, 2020 Apr 30]. J Vasc Surg. 2020;S0741-5214(20)31099-5.                           |
| 4  | 8.  | Ilonzo N, Vouyouka A, Han D, Tadros R, Kim SY, Love B, et al. The Importance of a          |
| 5  |     | Centralized Line Service during the COVID-19 Pandemic [published online ahead of           |
| 6  |     | print, 2020 May 14]. J Vasc Surg. 2020;S0741-5214(20)31158-7.                              |
| 7  | 9.  | American Society of Anesthesiologists Task Force on Central Venous Access, Rupp SM,        |
| 8  |     | Apfelbaum JL, Blitt C, Caplan RA, Connis RT, Domino KB, et al. Practice guidelines for     |
| 9  |     | central venous access: a report by the American Society of Anesthesiologists Task Force    |
| 10 |     | on Central Venous Access. Anesthesiology. 2012;116(3):539 573.                             |
| 11 | 10. | . Scoppettuolo G, Biasucci DG, Pittiruti M. Vascular access in COVID-19 patients: Smart    |
| 12 |     | decisions for maximal safety [published online ahead of print, 2020 May 5]. J Vasc         |
| 13 |     | Access. 2020;1129729820923935.   |
| 14 | 11. | . Conwell P, Aniskiewicz M, Ghidini J, DeVaux L, Perazella M, Giullian J. A Hospital-      |
| 15 |     | Based Program to Reduce Central Line-Associated Bloodstream Infections among               |
| 16 |     | Hospitalized Patients Receiving Hemodialysis Using a Central Venous Catheter for           |
| 17 |     | Vascular Access. Nephrol Nurs J. 2019;46(6):587 590.                                       |
| 18 | 12. | . Legemaat MM, Jongerden IP, van Rens RM, Zielman M, van den Hoogen A. Effect of a         |
| 19 |     | vascular access team on central line-associated bloodstream infections in infants admitted |
| 20 |     | to a neonatal intensive care unit: a systematic review. Int J Nurs Stud. 2015;52(5):1003 🗆 |
| 21 |     | 1010.  |

| 1  | 13. Pathak R, Gangina S, Jairam F, Hinton K. A vascular access and midlines program can     |
|----|---|
| 2  | decrease hospital-acquired central line-associated bloodstream infections and cost to a     |
| 3  | community-based hospital. Ther Clin Risk Manag. 2018;14:1453 1456.                          |
| 4  | 14. Lawrence PF, Baril DT, Woo K. Investigating uncommon vascular diseases using the        |
| 5  | Vascular Low Frequency Disease Consortium [published online ahead of print, 2020 Jan        |
| 6  | 18]. J Vasc Surg. 2020;S0741-5214(19)32781-8.   |
| 7  | 15. Mouawad NJ, Cuff RF, Hultgren R, Chuen J, Galeazzi E, Wohlauer M. The Vascular          |
| 8  | Surgery COVID-19 Collaborative (VASCC) [published online ahead of print, 2020 Apr           |
| 9  | 22]. J Vasc Surg. 2020;S0741-5214(20)31054-5.   |
| 10 | 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic      |
| 11 | data capture (REDCap)a metadata-driven methodology and workflow process for                 |
| 12 | providing translational research informatics support. J Biomed Inform. 2009;42(2):377       |
| 13 | 381.  |
| 14 | 17. Aitken P, Leggat P. Considerations in mass casualty and disaster management. In:        |
| 15 | Blaivas M, editor. Emergency medicine: an international perspective. Rijeka:                |
| 16 | IntechOpen; 2012. p. 145-182.   |
| 17 | 18. Sasangohar F, Jones SL, Masud FN, Vahidy FS, Kash BA. Provider Burnout and Fatigue      |
| 18 | During the COVID-19 Pandemic: Lessons Learned from a High-Volume Intensive Care             |
| 19 | Unit [published online ahead of print, 2020 Apr 9]. Anesth Analg.                           |
| 20 | 2020;10.1213/ANE.000000000004866.   |
| 21 | 19. Rasmussen TE, Koelling EE. A military perspective on the vascular surgeon's response to |
| 22 | the COVID-19 pandemic. J Vasc Surg. 2020;71(6):1821 1822.                                   |

| 1  | 20. Christie B, Weber P, DeMillo A, Chandler K, Reeves J, Anderson B, et al. Alarming rise        |
|----|---|
| 2  | in virus cases as states roll back lockdowns. Associated Press News. 10 <sup>th</sup> June, 2020. |
| 3  | Available at: https://apnews.com/feb4c26d9364497cf82ee7c0c1b1b3d5, accessed 11 <sup>th</sup>      |
| 4  | June, 2020.   |
| 5  | 21. Lamperti M, Bodenham AR, Pittiruti M, Blaivas M, Augoustides JG, Elbarbary M, et al.          |
| 6  | International evidence-based recommendations on ultrasound-guided vascular                        |
| 7  | access. Intensive Care Med. 2012;38(7):1105 1117.   |
| 8  | 22. Wicker S, Stirn AV, Rabenau HF, von Gierke L, Wutzler S, Stephan C. Needlestick               |
| 9  | injuries: causes, preventability and psychological impact. Infection. 2014;42(3):549 $\square$    |
| 10 | 552.  |
| 11 | 23. Spiezia L, Boscolo A, Poletto F, Cerruti L, Tiberio I, Campello E, et al. COVID-19-           |
| 12 | Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute           |
| 13 | Respiratory Failure. Thromb Haemost. 2020;120(6):998 1000.  |
| 14 | 24. Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al.              |
| 15 | Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 [published                  |
| 16 | online ahead of print, 2020 May 6]. Ann Intern Med. 2020;M20-2003.                                |
| 17 | 25. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM,                     |
| 18 | et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-           |
| 19 | 19. Thromb Res. 2020;191:145 \[] 147.   |
| 20 | 26. Oudemans-van Straaten HM, Wester JPJ, de Pont ACJM, Schetz MRC. Anticoagulation               |
| 21 | strategies in continuous renal replacement therapy: can the choice be evidence                    |
| 22 | based?. Intensive Care Med. 2006;32(2):188 202.   |

| 1  | 27. McGee DC, Gould MK. Preventing complications of central venous catheterization. N       |
|----|---|
| 2  | Engl J Med. 2003;348(12):1123 1133.   |
| 3  | 28. Merrer J, De Jonghe B, Golliot F, Lefrant JU, Raffy B, Barre E, et al. Complications of |
| 4  | femoral and subclavian venous catheterization in critically ill patients: a randomized      |
| 5  | controlled trial. JAMA. 2001;286(6):700 707.  |
| 6  | 29. Kornbau C, Lee KC, Hughes GD, Firstenberg MS. Central line complications. Int J Crit    |
| 7  | Illn Inj Sci. 2015;5(3):170 178.  |
| 8  | 30. Hameeteman M, Bode AS, Peppelenbosch AG, van der Sande FM, Tordoir JH.                  |
| 9  | Ultrasound-guided central venous catheter placement by surgical trainees: a safe            |
| 10 | procedure?. J Vasc Access. 2010;11(4):288 292.  |

**Table 1.** Hospital characteristics and central venous line placement volume

|                                | Hospitals with line team in<br>place or planned | Groups placing lines at their<br>hospital outside of line |
|--------------------------------|---|---|
|                                | n=44 (%)  | team  |
|                                | 11-44 (76)                                      | n=14 (%)  |
| Hospital characteristics       |   |   |
| Urban                          | 44 (100)  | 14 (100)  |
| Academic university            | 34 (77)   | 11 (79)   |
| affiliated                     | 4 (9)   | 2 (14)  |
| Non-university affiliated      | 3 (7)   | 1 (7)   |
| teaching                       |   | 2 (14)  |
| 0                              | 4 (9)   |   |
| Community/private<br>Public    | 1 (7)   | 5 (11)  |
|                                |   |   |
| Veterans affairs               |   |   |
| Hospital size by baseline beds | - 4   |   |
| 100-199                        | 5 (11)  | 1 (7)   |
| 200-299                        | 3 (7)   | 1 (7)   |
| 300-399                        | 6 (14)  | 1 (7)   |
| >400                           | 30 (68)   | 11 (79)   |
|                                | Hospitals with line teams in                    |   |
|                                | place   |   |
|                                | n=31 (%)  |   |
| Line placements in previous 7  |   |   |
| days*                          |   |   |
| 0-10                           | 7 (23)  |   |
| 10-20                          | 9 (29)  | NA  |
| 20-30                          | 2 (7)   |   |
| 30-40                          | 2 (7)   |   |
| >40                            | 11 (36)   |   |

\*Line placements in the 7 days preceding data entry into the study

|                                   | RIJ     | LIJ     | R SC    | L SC    | Fem     | GSV   | Рор   |
|-----------------------------------|---------|---------|---------|---------|---------|-------|-------|
|                                   | n (%)   | n (%) | n (%) |
| All anatomic                      |         |         |         |         |         |       |       |
| locations                         |         |         |         |         |         |       |       |
| considered viable                 |         |         |         |         |         |       |       |
| Prior to                          | 59 (97) | 58 (95) | 41 (67) | 39 (64) | 52 (85) | 2 (3) | 0 (0) |
| Pandemic                          |         |         |         |         |         |       |       |
| COVID-19+                         | 52 (85) | 50 (82) | 27 (44) | 26 (43) | 48 (79) | 4 (7) | 2 (3) |
| COVID-19PUI                       | 55 (90) | 51 (84) | 27 (44) | 27 (44) | 49 (80) | 4 (7) | 1 (2) |
| COVID-19-                         | 59 (97) | 58 (95) | 34 (56) | 32 (53) | 49 (80) | 2 (3) | 0 (0) |
|                                   |         |         |         |         |         |       |       |
| 1 <sup>st</sup> choice for supine |         |         |         |         |         |       |       |
| patient                           |         |         |         |         |         |       |       |
| COVID-19+                         |         |         |         |         |         |       |       |
| TLC                               | 31 (53) | 22 (37) | 2 (3)   | 0 (0)   | 4 (7)   | 0 (0) | 0 (0) |
| HDC                               | 46 (82) | 0 (0)   | 2 (3)   | 0 (0)   | 8 (14)  | 0 (0) | 0 (0) |
| COVID-19PUI                       |         |         |         |         |         |       |       |
| TLC                               | 30 (51) | 23 (39) | 2 (3)   | 0 (0)   | 4 (7)   | 0 (0) | 0 (0) |
| HDC                               | 45 (80) | 0 (0)   | 2 (3)   | 0 (0)   | 9 (16)  | 0 (0) | 0 (0) |

**Table 2.** Anatomic preferences for central venous catheter placements by COVID-19 status

R IJ: right internal jugular vein; L IJ: left internal jugular vein; R SC: right subclavian vein; L SC: left subclavian vein; Fem: femoral vein; GSV: greater saphenous vein; Pop: popliteal vein; COVID-19+: patient who has tested positive for SARS-CoV-2 virus; COVID-19PUI: patient under investigation for SARS-CoV-2 infection; COVID-19-: patient who has not tested positive for SARS-CoV-2 virus; TLC: triple lumen catheter; HDC: hemodialysis catheter

|                             | COVID-19+ (%) | COVID-19PUI | COVID-19- (%) |
|-----------------------------|---------------|-------------|---------------|
|                             |               | (%)         |               |
| Surgical mask without N95   | 1 (2)         | 2 (3)       | 41 (67)       |
| N95 without surgical mask   | 15 (25)       | 13 (21)     | 6 (10)        |
| N95 with surgical mask over | 45 (74)       | 46 (75)     | 12 (20)       |
| Powered air-purifying       | 10 (16)       | 8 (13)      | 2 (3)         |
| respirator                  |               |             |               |
| Face shield                 | 54 (89)       | 55 (90)     | 36 (59)       |
| Gown                        | 55 (90)       | 54 (89)     | 55 (90)       |
| Bunny suit with hood        | 5 (8)         | 4 (7)       | 0 (0)         |
| Bunny suit without hood     | 3 (5)         | 3 (5)       | 0 (0)         |
| Bouffant/surgical cap       | 52 (85)       | 52 (85)     | 48 (79)       |
| Goggles                     | 2 (3)         | 1 (2)       | 0 (0)         |

**Table 3.** Personal protective equipment used during placement of central venous linespopulations by COVID-19 status

COVID-19+: patient who has tested positive for SARS-CoV-2 virus; COVID-19PUI: patient under investigation for SARS-CoV-2 infection; COVID-19-: patient who has not tested positive for SARS-CoV-2 virus

|  |                             |                      |              | Anatom | ic Location |                                |   |   |
|--|-----------------------------|----------------------|--------------|--------|-------------|--------------------------------|---|---|
| Complication   | Total<br>Number of<br>cases | Number of related to | IJ / Carotid | SC     | Fem         | Other                          | Initial Management Strategy   | Initial Management<br>Success               |
| Inadvertent arterial<br>puncture with wire in<br>place prior to<br>catheter placement                              | 3                           | 0                    | 2            | 0      | 1           |                                | Pull line and hold pressure (1)<br>Open surgical repair (1)<br>Other (1)  | Yes<br>Yes<br>*                             |
| Inadvertent arterial<br>puncture with dilator<br>in place prior to<br>catheter placement                           | 2                           | 0                    | 1            | 0      | 0           | Descending<br>aorta            | Pull line and hold pressure (1),<br>Endovascular mgmt w stent (1)   | Yes<br>Yes                                  |
| Inadvertent arterial<br>placement with<br>catheter still<br>remaining in artery                                    | 16                          | 1                    | 5            | 6      | 4           | Brachio-<br>cephalic<br>artery | Pull line and hold pressure (5),<br>Endovascular mgmt w balloon (2),<br>Closure device (1),<br>Endovascular mgmt w stent graft (1),<br>Open surgical repair (3),<br>Used as arterial line then pulled (1)<br>Other (3)* | Yes<br>Yes<br>Yes<br>Yes<br>Yes<br>Yes<br>* |
| Inadvertent arterial<br>puncture with no<br>catheter remaining in<br>artery but active<br>extravasation<br>present | 2                           | 0                    | 0            | 1      | 1           |                                | Pull line and hold pressure (2)   | Yes   |
| Catheter or wire   | 3                           | 0                    | 0            | 0      | 1           | aorta                          | Open surgical retrieval (1)   | Yes   |

1

1

right atrium

Anticoagulation (2)

Pull line and hold pressure (10)

Yes

**Table 4.** latrogenic complications of central venous line placement in COVID-19+ patients managed by participating sites.

fracture/embolizatio

Hematoma or active

bleeding at catheter site with catheter in place and catheter in 10

6

8

n

| correct position |    |   |   |   |   |           |                        |     |
|------------------|----|---|---|---|---|-----------|------------------------|-----|
| Pneumothorax     | 11 | 1 | 4 | 5 | 0 | 2 unknown | Tube thoracostomy (11) | Yes |
| Air embolism     | 1  | 1 | 1 | 0 | 0 |           | None attempted         | No  |

\*see text; IJ: internal jugular, SC: subclavian, fem: femoral

Figure 1.





Figure 2. Types of central venous lines placed by line teams (n=44).



TLC: triple lumen catheter; NTHDC: non-tunneled hemodialysis catheter; THDC: tunneled hemodialysis catheter; VV ECMO: veno-venous extracorporeal membrane oxygenation; AV ECMO: arterio-venous extracorporeal membrane oxygenation; PD: peritoneal dialysis; PICC: peripherally inserted central catheter; Others include: Infusaports, Hickman catheters and small bore sheaths for potential ECMO candidates **Figure 1.** Central Venous Access Line Team Composition. VS: Vascular Surgery; GS: General Surgery: IR: Interventional Radiology; Card: Cardiology; CTS: Cardiothoracic Surgery; Med: Medicine; Anes: Anesthesia.

\*Percentage of Line Teams that Include Attending Physicians and Trainees of Each Specialty

**Figure 2.** Types of central venous lines placed by line teams (n=44). TLC: triple lumen catheter; NTHDC: non-tunneled hemodialysis catheter; THDC: tunneled hemodialysis catheter; VV ECMO: veno-venous extracorporeal membrane oxygenation; AV ECMO: arterio-venous extracorporeal membrane oxygenation; PD: peritoneal dialysis; PICC: peripherally inserted central catheter; Others include: Infusaports, Hickman catheters and small bore sheaths for potential ECMO candidates

**Table 1.** Hospital characteristics and central venous line placement volume. \*Line placements in

 the 7 days preceding data entry into the study

**Table 2.** Anatomic preferences for central venous catheter placements by COVID-19 status. R IJ: right internal jugular vein; L IJ: left internal jugular vein; R SC: right subclavian vein; L SC: left subclavian vein; Fem: femoral vein; GSV: greater saphenous vein; Pop: popliteal vein; COVID-19+: patient who has tested positive for SARS-CoV-2 virus; COVID-19PUI: patient under investigation for SARS-CoV-2 infection; COVID-19-: patient who has not tested positive for SARS-CoV-2 virus; TLC: triple lumen catheter; HDC: hemodialysis catheter 

 Table 3. Personal protective equipment used during placement of central venous lines

 populations by COVID-19 status. COVID-19+: patient who has tested positive for SARS-CoV-2

 virus; COVID-19PUI: patient under investigation for SARS-CoV-2 infection; COVID-19-:

 patient who has not tested positive for SARS-CoV-2 virus

**Table 4.** Iatrogenic complications of central venous line placement in COVID-19+ patients

 managed by participating sites. \*see text; IJ: internal jugular, SC: subclavian, fem: femoral

Appendix A. Hospitals represented in this study.

Appendix B: Items placed on dedicated line carts used by line teams.

Appendix C: Recommended items on a dedicated line cart

| Country       | Stat<br>e | Hospital   |
|---------------|-----------|--|
| Canada        |           | Vancouver General Hospital   |
| France        |           | Ambroise Paré University Hospital, AP-HP                               |
| Germany       |           | University Medical Center Hamburg-Eppendorf                            |
| Greece        |           | General Hospital of Athens KAT   |
| India         |           | Medanta Hospital   |
|               |           | Postgraduate Institute of Medical Education and Research               |
| Italy         |           | Policlinico Gaetano Martino  |
| Korea (South) |           | Kyung Hee University Hospital at Gangdong                              |
| Mexico        |           | Instituto Nacional de Ciencias Médicas y Nutrición Salvador<br>Zubirán |
| New Zealand   |           | Waikato Hospital   |
| Singapore     | 1         | National University Hospital   |
| Sri Lanka     | 1         | National Institute of Nephrology Dialysis and Transplantation          |
| Switzerland   |           | University Hospital Zurich   |
|               | AZ        | Banner University Medical Center-Tucson                                |
|               | AZ        | Mayo Clinic Hospital   |
|               | CA        | Community Regional Medical Center                                      |
|               | CA        | Olive View- UCLA Medical Center  |
|               | CA        | Palo Alto Veterans Affairs Medical Center                              |
|               | CA        | Ronald Reagan UCLA Medical Center                                      |
|               | CA        | Veterans Affairs Greater Los Angeles                                   |
|               | CO        | Rocky Mountain Regional Veterans Affairs Medical Center                |
|               | CO        | Rose Medical Center  |
|               | CO        | University of Colorado Anschutz Medical Campus                         |
|               | IA        | University of Iowa Hospitals and Clinics                               |
|               | IL        | Loyola University Medical Center                                       |
|               | IL        | NorthShore University Health System                                    |
|               | IL        | Northwestern Memorial Hospital   |
|               | IN        | Eskenazi Health  |
|               | IN        | Indiana University Health Methodist Hospital                           |
|               | IN        | Indiana University Health North Hospital                               |
|               | IN        | Indiana University Health West Hospital                                |
|               | LA        | Our Lady of the Lake   |
|               | LA        | West Jefferson Medical Center  |
|               | MA        | Boston Medical Center  |
|               | MA        | Massachusetts General Hospital   |
|               | MA        | University of Massachusetts Medical Center                             |
|               | MD        | The Johns Hopkins Hospital   |
|               | MI        | Henry Ford Hospital  |
|               | MI        | McLaren Bay Region   |
|               | MI        | McLaren Flint  |

Appendix A. Hospitals represented in this study.

| MO | St. Louis University Hospital                            |
|----|--|
| NJ | Overlook Medical Center                                  |
| NJ | Rutgers Robert Wood Johnson University Hospital          |
| NJ | University Hospital                                      |
| NY | Jacobi Medical Center                                    |
| NY | Montefiore Medical Center                                |
| NY | Mount Sinai Brooklyn                                     |
| NY | The Mount Sinai Hospital                                 |
| NY | Mount Sinai Queens                                       |
| NY | New York-Presbyterian Columbia University Medical Center |
| NY | New York- Presbyterian Queens                            |
| NY | North Shore University Hospital, Northwell Health        |
| NY | Weill Cornell Medicine                                   |
| TX | Audie L Murphy Veterans Affairs Hospital                 |
| TX | Dallas Veterans Affairs Medical Center                   |
| TX | Memorial Hermann-Texas Medical Center                    |
| TX | University of Texas Health Science Center at San Antonio |
|    | University Hospital                                      |
| UT | University of Utah Hospital                              |
| VA | Virginia Commonwealth University Medical Center          |
| WA | University of Washington Medical Center                  |

Appendix B: Items placed on dedicated line carts used by line teams.

| Item                            | (%)  |
|---------------------------------|------|
| Central line kits               | 100  |
| Sterile gloves                  | 97.1 |
| Sterile gowns                   | 97.1 |
| Sterile preparation sticks      | 94.3 |
| Sterile gauze                   | 94.3 |
| Ultrasound probe cover          | 94.3 |
| Selection of syringes           | 91.4 |
| Sterile saline flush            | 91.4 |
| Sutures                         | 91.4 |
| Masks                           | 91.4 |
| Bouffant hats                   | 85.7 |
| Selection of hypodermic needles | 80.0 |
| Surgical towels                 | 80.0 |
| Таре                            | 77.1 |
| Selection of sterile drapes     | 77.1 |
| Face shields                    | 77.1 |
| Lidocaine                       | 74.3 |
| Micropuncture sets              | 74.3 |
| 3-way stopcock                  | 71.4 |
| Antimicrobial dressing          | 71.4 |
|                                 |      |

#### Appendix C: Recommended items on a dedicated line cart

PPE:

Gloves Gowns Bouffant head covering Masks: surgical, N95 Face Shields Boot covers

### Non-sterile items:

Tape Coban Arm boards

### Sterile items:

Central Line Kits Non-tunneled hemodialysis access kits Arterial line kits (Arrow, micropuncture) 12" extension tubing Surgical towels Drapes: for arterial lines, central lines Sterile gloves Sterile gowns Sterile preparation sticks Sterile gauze Selection of syringes Selection of hypodermic needles Suture Ultrasound probe cover Lidocaine 3-way stopcock Antimicrobial dressing